Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 Tablets in Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07432854 is registered in ClinicalTrials.gov with Dermavon Holdings Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 Tablets in Adult Patients With Moderate to Severe Plaque Psoriasis
- Lead sponsor
- Dermavon Holdings Limited
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- March 3, 2026
- Completion date
- July 30, 2028
- Enrollment
- 540 (estimated)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.
moderate to severe plaque psoriasis